As an estimated 30,000 cancer specialists prepare to converge on the city of Chicago in a couple of weeks for the so-called "Super Bowl of Cancer" - or, as analysts at Wedbush PacGrow Life Sciences put it, "the most important and most unmanageable" of the annual biotech meetings - investors already have been placing their bets on companies expected to wow attendees at this year's American Society of Clinical Oncology meeting. (BioWorld Today) Read More
